Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 papers

DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM


  Ischemic Heart Disease

  Free Subscription


Articles published in Am Heart J

Retrieve available abstracts of 284 articles:
HTML format



Single Articles


    May 2020
  1. DEHGHANI P, Davidson LJ, Grines CL, Nayak K, et al
    North American COVID-19 ST-segment elevation myocardial infarction (NACMI) registry: Rationale, design, and implications.
    Am Heart J. 2020 May 16. pii: S0002-8703(20)30142.
    PubMed     Abstract available


  2. KUNO T, Takahashi M, Obata R, Maeda T, et al
    Cardiovascular comorbidities, cardiac injury and prognosis of COVID-19 in New York City.
    Am Heart J. 2020 May 15. pii: S0002-8703(20)30141.
    PubMed     Abstract available


  3. LOUNGANI RS, Rehorn MR, Newby LK, Katz JN, et al
    A care pathway for the cardiovascular complications of COVID-19: Insights from an institutional response.
    Am Heart J. 2020;225:3-9.
    PubMed     Abstract available


    April 2020
  4. GALES J, Krasuski RA, Awerbach JD
    Emergency department evaluation of chest pain among adult congenital heart disease patients.
    Am Heart J. 2020;222:191-198.
    PubMed     Abstract available


  5. STEGEHUIS VE, Wijntjens GWM, van de Hoef TP, Casadonte L, et al
    Distal Evaluation of Functional performance with Intravascular sensors to assess the Narrowing Effect-combined pressure and Doppler FLOW velocity measurements (DEFINE-FLOW) trial: Rationale and trial design.
    Am Heart J. 2020;222:139-146.
    PubMed     Abstract available


  6. HAUW-BERLEMONT C, Lamhaut L, Diehl JL, Andreotti C, et al
    EMERGEncy versus delayed coronary angiogram in survivors of out-of-hospital cardiac arrest with no obvious non-cardiac cause of arrest: Design of the EMERGE trial.
    Am Heart J. 2020;222:131-138.
    PubMed     Abstract available


    March 2020
  7. WU CM, Albert NM, Gluckman TJ, Lu D, et al
    Facilitating the identification of patients hospitalized for acute myocardial infarction and heart failure and the assessment of their readmission risk through the Patient Navigator Program.
    Am Heart J. 2020;224:77-84.
    PubMed     Abstract available


  8. YOON YH, Ahn JM, Kang DY, Park H, et al
    Pragmatic trial comparing routine versus no routine functional testing in high-risk patients who underwent percutaneous coronary intervention: Rationale and design of POST-PCI trial.
    Am Heart J. 2020;224:156-165.
    PubMed     Abstract available


  9. BODEN WE, Miller MG, McBride R, Harvey C, et al
    Testosterone concentrations and risk of cardiovascular events in androgen-deficient men with atherosclerotic cardiovascular disease.
    Am Heart J. 2020;224:65-76.
    PubMed     Abstract available


  10. PARADIES V, Zheng H, Chan MHH, Chan MYY, et al
    Impact of time of onset of symptom of ST-segment elevation myocardial infarction on 1-year rehospitalization for heart failure and mortality.
    Am Heart J. 2020;224:1-9.
    PubMed     Abstract available


  11. OSMAN M, Saleem M, Osman K, Kheiri B, et al
    Radial versus femoral access for percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction: Trial sequential analysis.
    Am Heart J. 2020;224:98-104.
    PubMed     Abstract available


  12. RAGNARSSON S, Janiec M, Modrau IS, Dreifaldt M, et al
    No-touch saphenous vein grafts in coronary artery surgery (SWEDEGRAFT): Rationale and design of a multicenter, prospective, registry-based randomized clinical trial.
    Am Heart J. 2020;224:17-24.
    PubMed     Abstract available


  13. SMILOWITZ NR, Alviar CL, Katz SD, Hochman JS, et al
    Coronary artery bypass grafting versus percutaneous coronary intervention for myocardial infarction complicated by cardiogenic shock.
    Am Heart J. 2020 Mar 12. pii: S0002-8703(20)30080.
    PubMed     Abstract available


  14. VLACHOJANNIS GJ, Vogel RF, Wilschut JM, Lemmert ME, et al
    COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: Rationale and design of the COMPARE CRUSH trial.
    Am Heart J. 2020;224:10-16.
    PubMed     Abstract available


  15. LAU G, Koh M, Kavsak PA, Schull MJ, et al
    Clinical outcomes for chest pain patients discharged home from emergency departments using high-sensitivity versus conventional cardiac troponin assays.
    Am Heart J. 2020;221:84-94.
    PubMed     Abstract available


  16. G TOTH G, Lansky A, Baumbach A, Kelbaek H, et al
    Validation of the all-comers design: Results of the TARGET-AC substudy.
    Am Heart J. 2020;221:148-154.
    PubMed     Abstract available


    February 2020
  17. DAUBERT MA, White JA, Al-Khalidi HR, Velazquez EJ, et al
    Cardiac remodeling after large ST-elevation myocardial infarction in the current therapeutic era.
    Am Heart J. 2020;223:87-97.
    PubMed     Abstract available


  18. PEARSON GD, Mensah GA, Rosenberg Y, Stoney CM, et al
    National Heart, Lung, and Blood Institute cardiovascular clinical trial perspective.
    Am Heart J. 2020;224:25-34.
    PubMed     Abstract available


  19. SONG L, Tu S, Sun Z, Wang Y, et al
    Quantitative flow ratio-guided strategy versus angiography-guided strategy for percutaneous coronary intervention: Rationale and design of the FAVOR III China trial.
    Am Heart J. 2020;223:72-80.
    PubMed     Abstract available


  20. JAWITZ OK, Gulack BC, Brennan JM, Thibault DP, et al
    Association of postoperative complications and outcomes following coronary artery bypass grafting.
    Am Heart J. 2020;222:220-228.
    PubMed     Abstract available


  21. QUESADA O, AlBadri A, Wei J, Shufelt C, et al
    Design, methodology and baseline characteristics of the Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction (WISE-CVD).
    Am Heart J. 2020;220:224-236.
    PubMed     Abstract available


  22. D'ASCENZO F, Biole C, Raposeiras-Roubin S, Gaido F, et al
    Average daily ischemic versus bleeding risk in patients with ACS undergoing PCI: Insights from the BleeMACS and RENAMI registries.
    Am Heart J. 2020;220:108-115.
    PubMed     Abstract available


    January 2020
  23. HOUSSANY-PISSOT S, Rosencher J, Allouch P, Bensouda C, et al
    Screening coronary artery disease with computed tomography angiogram should limit normal invasive coronary angiogram, regardless of pretest probability.
    Am Heart J. 2020 Jan 30. pii: S0002-8703(20)30034.
    PubMed     Abstract available


  24. VALLABHAJOSYULA S, Vallabhajosyula S, Burstein B, Ternus BW, et al
    Epidemiology of in-hospital cardiac arrest complicating non-ST-segment elevation myocardial infarction receiving early coronary angiography.
    Am Heart J. 2020;223:59-64.
    PubMed     Abstract available


  25. FOX KAA, Anand SS, Aboyans V, Cowie MR, et al
    Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic
    Am Heart J. 2020;222:166-173.
    PubMed     Abstract available


  26. ROMAGUERA R, Salinas P, Brugaletta S, Gomez-Lara J, et al
    Second-Generation Drug-Eluting Stents in Diabetes (SUGAR) trial: Rationale and study design.
    Am Heart J. 2020;222:174-182.
    PubMed    


  27. JEONG YJ, Park K, Kim YD
    Comparison between ticagrelor and clopidogrel on myocardial blood flow in patients with acute coronary syndrome, using 13 N-ammonia positron emission tomography.
    Am Heart J. 2020;222:121-130.
    PubMed     Abstract available


  28. DUENGEN HD, Kim RJ, Zahger D, Orvin K, et al
    Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction-Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial.
    Am Heart J. 2020;224:129-137.
    PubMed     Abstract available


  29. TARDIF JC, Dube MP, Pfeffer MA, Waters DD, et al
    Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib.
    Am Heart J. 2020;222:157-165.
    PubMed     Abstract available


  30. KINNAIRD T, Gallagher S, Spratt JC, Ludman P, et al
    Complex high-risk and indicated percutaneous coronary intervention for stable angina: Does operator volume influence patient outcome?
    Am Heart J. 2020;222:15-25.
    PubMed     Abstract available


  31. DALGAARD F, North R, Pieper K, Fonarow GC, et al
    Risk of major cardiovascular and neurologic events with obstructive sleep apnea among patients with atrial fibrillation.
    Am Heart J. 2020;223:65-71.
    PubMed     Abstract available


  32. CASSESE S, Ndrepepa G, Byrne RA, Laugwitz KL, et al
    Ticagrelor-based antiplatelet regimens in patients with atherosclerotic artery disease-A meta-analysis of randomized clinical trials.
    Am Heart J. 2020;219:109-116.
    PubMed     Abstract available


  33. NANNA MG, Peterson ED, Wu A, Harding T, et al
    Age, knowledge, preferences, and risk tolerance for invasive cardiac care.
    Am Heart J. 2020;219:99-108.
    PubMed     Abstract available


  34. SAMSKY M, Krucoff M, Althouse AD, Abraham WT, et al
    Clinical and regulatory landscape for cardiogenic shock: A report from the Cardiac Safety Research Consortium ThinkTank on cardiogenic shock.
    Am Heart J. 2020;219:1-8.
    PubMed    


    December 2019
  35. PUYMIRAT E, Simon T, de Bruyne B, Montalescot G, et al
    Rationale and design of the Flow Evaluation to Guide Revascularization in Multivessel ST-Elevation Myocardial Infarction (FLOWER-MI) trial.
    Am Heart J. 2019;222:1-7.
    PubMed     Abstract available


  36. MUHLESTEIN JB, Anderson JL, Bethea CF, Severance HW, et al
    Feasibility of combining serial smartphone single-lead electrocardiograms for the diagnosis of ST-elevation myocardial infarction.
    Am Heart J. 2019;221:125-135.
    PubMed     Abstract available


  37. KALRA R, Shenoy C
    Identifying nonischemic cardiomyopathy patients who would benefit from an implantable cardioverter-defibrillator: Can late gadolinium enhancement on cardiovascular magnetic resonance imaging help?
    Am Heart J. 2019 Dec 17. pii: S0002-8703(19)30352.
    PubMed    


  38. SALAHUDDIN T, Kittelson J, Tardif JC, Shah PK, et al
    Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial.
    Am Heart J. 2019;221:60-66.
    PubMed     Abstract available


  39. SHLOFMITZ E, Torguson R, Zhang C, Craig PE, et al
    Impact of Intravascular Ultrasound on Outcomes Following PErcutaneous Coronary InterventioN in Complex Lesions (iOPEN Complex).
    Am Heart J. 2019;221:74-83.
    PubMed     Abstract available


  40. WILLEMSEN LM, Janssen PWA, Hackeng CM, Kelder JC, et al
    A randomized, double-blind, placebo-controlled trial investigating the effect of ticagrelor on saphenous vein graft patency in patients undergoing coronary artery bypass grafting surgery-Rationale and design of the POPular CABG trial.
    Am Heart J. 2019;220:237-245.
    PubMed     Abstract available


  41. TRIPOLT NJ, Kolesnik E, Pferschy PN, Verheyen N, et al
    Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction-The EMMY trial.
    Am Heart J. 2019;221:39-47.
    PubMed     Abstract available


  42. PATEL DM, Thiessen-Philbrook H, Brown JR, McArthur E, et al
    Association of plasma-soluble ST2 and galectin-3 with cardiovascular events and mortality following cardiac surgery.
    Am Heart J. 2019;220:253-263.
    PubMed     Abstract available


  43. SIDIK NP, McEntegart M, Roditi G, Ford TJ, et al
    Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Function and CT Coronary Angiogram (CorCTCA) study.
    Am Heart J. 2019;221:48-59.
    PubMed     Abstract available


  44. MAZUREK M, Teutsch C, Diener HC, Dubner SJ, et al
    Safety and effectiveness of dabigatran at 2 years: Final outcomes from Phase II of the GLORIA-AF registry program.
    Am Heart J. 2019;218:123-127.
    PubMed     Abstract available


  45. RYMER JA, O'Donnell CI, Plomondon ME, Hess PL, et al
    Same-day discharge among patients undergoing elective PCI: Insights from the VA CART Program.
    Am Heart J. 2019;218:75-83.
    PubMed     Abstract available


    November 2019
  46. DE FERRARI GM, Stevens SR, Ambrosio G, Leonardi S, et al
    Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS.
    Am Heart J. 2019;220:82-88.
    PubMed     Abstract available


  47. TOFLER GH, Morel-Kopp MC, Spinaze M, Dent J, et al
    The effect of metoprolol and aspirin on cardiovascular risk in bereavement: A randomized controlled trial.
    Am Heart J. 2019;220:264-272.
    PubMed     Abstract available


  48. YANG D, O'Brien CG, Ikeda G, Traverse JH, et al
    Meta-analysis of short- and long-term efficacy of mononuclear cell transplantation in patients with myocardial infarction.
    Am Heart J. 2019;220:155-175.
    PubMed     Abstract available


  49. SHAVADIA JS, Granger CB, Alemayehu W, Westerhout CM, et al
    High-throughput targeted proteomics discovery approach and spontaneous reperfusion in ST-segment elevation myocardial infarction.
    Am Heart J. 2019;220:137-144.
    PubMed     Abstract available


  50. LORING Z, Shrader P, Allen LA, Blanco R, et al
    Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation.
    Am Heart J. 2019;219:21-30.
    PubMed     Abstract available


    October 2019
  51. CANNON CP, de Lemos JA, Rosenson RS, Ballantyne CM, et al
    Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States.
    Am Heart J. 2019;219:70-77.
    PubMed     Abstract available


  52. JENTZER JC, Baran DA, van Diepen S, Barsness GW, et al
    Admission Society for Cardiovascular Angiography and Intervention shock stage stratifies post-discharge mortality risk in cardiac intensive care unit patients.
    Am Heart J. 2019;219:37-46.
    PubMed     Abstract available


  53. WELSH RC, Peterson ED, De Caterina R, Bode C, et al
    Applying contemporary antithrombotic therapy in the secondary prevention of chronic atherosclerotic cardiovascular disease.
    Am Heart J. 2019;218:100-109.
    PubMed     Abstract available


  54. CHLEBUS K, Zdrojewski T, Gruchala M, Galaska R, et al
    Cardiovascular risk factor profiles in familial hypercholesterolemia patients with and without genetic mutation compared to a nationally representative sample of adults in a high-risk European country.
    Am Heart J. 2019;218:32-45.
    PubMed     Abstract available


  55. RYMER JA, Mandawat A, Abbott JD, Cohen MG, et al
    Opportunities for enhancing the care of older patients with ST-elevation myocardial infarction presenting for primary percutaneous coronary intervention: Rationale and design of the SAFE-STEMI for Seniors trial.
    Am Heart J. 2019;218:84-91.
    PubMed     Abstract available


  56. SHAVADIA JS, Zheng Y, Green JB, Armstrong PW, et al
    Associations between beta-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease.
    Am Heart J. 2019;218:92-99.
    PubMed     Abstract available


  57. PAGIDIPATI NJ, Zheng Y, Green JB, McGuire DK, et al
    Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS.
    Am Heart J. 2019;219:47-57.
    PubMed     Abstract available


  58. NIDORF SM, Fiolet ATL, Eikelboom JW, Schut A, et al
    The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics.
    Am Heart J. 2019;218:46-56.
    PubMed     Abstract available


  59. JONES WS, Kennedy KF, Hawkins BM, Attaran RR, et al
    Expanding opportunities to understand quality and outcomes of peripheral vascular interventions: The ACC NCDR PVI Registry.
    Am Heart J. 2019;216:74-81.
    PubMed     Abstract available


  60. CZOBOR P, Hung YY, Baer D, McGlothlin D, et al
    Amyloid cardiomyopathy in a large integrated health care system.
    Am Heart J. 2019;216:42-52.
    PubMed     Abstract available


    September 2019
  61. BRENNAN JM, Wruck L, Pencina MJ, Clare RM, et al
    Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials.
    Am Heart J. 2019;218:110-122.
    PubMed     Abstract available


  62. FERREIRA JP, Rossignol P, Dewan P, Lamiral Z, et al
    Income level and inequality as complement to geographical differences in cardiovascular trials.
    Am Heart J. 2019;218:66-74.
    PubMed     Abstract available


  63. LOWENSTERN A, Wu J, Bradley SM, Fanaroff AC, et al
    Current landscape of hybrid revascularization: A report from the NCDR CathPCI Registry.
    Am Heart J. 2019;215:167-177.
    PubMed     Abstract available


    August 2019
  64. PARK S, Ahn JM, Lee K, Kwon O, et al
    Long-term (10-year) outcomes of stenting or bypass surgery for acute coronary syndromes and stable ischemic heart disease with unprotected left main coronary artery disease.
    Am Heart J. 2019;218:9-19.
    PubMed     Abstract available


  65. DECKER PA, Larson NB, Bell EJ, Pankow JS, et al
    Erratum to "Increased hepatocyte growth factor levels over 2 years are associated with coronary heart disease: The Multi-Ethnic Study of Atherosclerosis (MESA)" [Am Heart J (2019) 30-34].
    Am Heart J. 2019 Aug 19. pii: S0002-8703(19)30176.
    PubMed    


  66. PAUL S, Judd SE, Howard VJ, Safford MS, et al
    Association of 25-hydroxyvitamin D with incident coronary heart disease in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study.
    Am Heart J. 2019;217:140-147.
    PubMed     Abstract available


  67. BRELLENTHIN AG, Lanningham-Foster LM, Kohut ML, Li Y, et al
    Comparison of the Cardiovascular Benefits of Resistance, Aerobic, and Combined Exercise (CardioRACE): Rationale, design, and methods.
    Am Heart J. 2019;217:101-111.
    PubMed     Abstract available


  68. CASTAGNO M, Menegon V, Monzani A, Zanetta S, et al
    Small-for-gestational-age birth is linked to cardiovascular dysfunction in early childhood.
    Am Heart J. 2019;217:84-93.
    PubMed     Abstract available


  69. RAY KK, Nicholls SJ, Ginsberg HD, Johansson JO, et al
    Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial.
    Am Heart J. 2019;217:72-83.
    PubMed     Abstract available


  70. VALENTE AM, Landzberg MJ, Gauvreau K, Egidy-Assenza G, et al
    Standardized outcomes in reproductive cardiovascular care: The STORCC initiative.
    Am Heart J. 2019;217:112-120.
    PubMed     Abstract available


  71. UDESEN NJ, Moller JE, Lindholm MG, Eiskjaer H, et al
    Rationale and design of DanGer shock: Danish-German cardiogenic shock trial.
    Am Heart J. 2019;214:60-68.
    PubMed     Abstract available


    July 2019
  72. TREBUCHET A, Julia C, Fezeu L, Touvier M, et al
    Prospective association between several dietary scores and risk of cardiovascular diseases: Is the Mediterranean diet equally associated to cardiovascular diseases compared to National Nutritional Scores?
    Am Heart J. 2019;217:1-12.
    PubMed     Abstract available


  73. RAMASAMY A, Serruys PW, Jones DA, Johnson TW, et al
    Reliable in vivo intravascular imaging plaque characterization: A challenge unmet.
    Am Heart J. 2019;218:20-31.
    PubMed     Abstract available


  74. SMILOWITZ NR, Lorin J, Berger JS
    Risks of noncardiac surgery early after percutaneous coronary intervention.
    Am Heart J. 2019;217:64-71.
    PubMed     Abstract available


  75. OKEKE NL, Webel AR, Bosworth HB, Aifah A, et al
    Rationale and design of a nurse-led intervention to extend the HIV treatment cascade for cardiovascular disease prevention trial (EXTRA-CVD).
    Am Heart J. 2019;216:91-101.
    PubMed     Abstract available


  76. MOK Y, Sang Y, Ballew SH, Hoogeveen RC, et al
    Premorbid levels of high-sensitivity cardiac troponin T and natriuretic peptide and prognosis after incident myocardial infarction.
    Am Heart J. 2019;216:62-73.
    PubMed     Abstract available


  77. MAURI L, Doros G, Rao SV, Cohen DJ, et al
    The OPTIMIZE randomized trial to assess safety and efficacy of the Svelte IDS and RX Sirolimus-eluting coronary stent Systems for the Treatment of atherosclerotic lesions: Trial design and rationale.
    Am Heart J. 2019;216:82-90.
    PubMed     Abstract available


  78. FARIDI KF, Rymer JA, Rao SV, Dai D, et al
    Ad hoc percutaneous coronary intervention in patients with stable coronary artery disease: A report from the National Cardiovascular Data Registry CathPCI Registry.
    Am Heart J. 2019;216:53-61.
    PubMed     Abstract available


  79. FU EL, Franko MA, Obergfell A, Dekker FW, et al
    High-sensitivity C-reactive protein and the risk of chronic kidney disease progression or acute kidney injury in post-myocardial infarction patients.
    Am Heart J. 2019;216:20-29.
    PubMed     Abstract available


  80. KONIGSTEIN M, Madhavan MV, Ben-Yehuda O, Rahim HM, et al
    Incidence and predictors of target lesion failure in patients undergoing contemporary DES implantation-Individual patient data pooled analysis from 6 randomized controlled trials.
    Am Heart J. 2019;213:105-111.
    PubMed     Abstract available


    June 2019
  81. WEBER B, Bersch-Ferreira AC, Torreglosa CR, Marcadenti A, et al
    Implementation of a Brazilian Cardioprotective Nutritional (BALANCE) Program for improvement on quality of diet and secondary prevention of cardiovascular events: A randomized, multicenter trial.
    Am Heart J. 2019;215:187-197.
    PubMed     Abstract available


  82. KUKULA K, Urbanowicz A, Klopotowski M, Dabrowski M, et al
    Long-term follow-up and safety assessment of angiogenic gene therapy trial VIF-CAD: Transcatheter intramyocardial administration of a bicistronic plasmid expressing VEGF-A165/bFGF cDNA for the treatment of refractory coronary artery disease.
    Am Heart J. 2019;215:78-82.
    PubMed     Abstract available


  83. JOSHI R, Agrawal T, Fathima F, Usha T, et al
    Cardiovascular risk factor reduction by community health workers in rural India: A cluster randomized trial.
    Am Heart J. 2019;216:9-19.
    PubMed     Abstract available


  84. MEHTA SR, Wood DA, Meeks B, Storey RF, et al
    Design and rationale of the COMPLETE trial: A randomized, comparative effectiveness study of complete versus culprit-only percutaneous coronary intervention to treat multivessel coronary artery disease in patients presenting with ST-segment elevation
    Am Heart J. 2019;215:157-166.
    PubMed     Abstract available


  85. HENNESSY T, Soh L, Bowman M, Kurup R, et al
    The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: A pilot randomized placebo controlled trial of colchicine following acute myocardial infarction.
    Am Heart J. 2019;215:62-69.
    PubMed     Abstract available


  86. CABEZA DE BACA T, Burroughs Pena MS, Slopen N, Williams D, et al
    Financial strain and ideal cardiovascular health in middle-aged and older women: Data from the Women's health study.
    Am Heart J. 2019;215:129-138.
    PubMed     Abstract available


  87. HALL TS, von Lueder TG, Zannad F, Rossignol P, et al
    Left ventricular ejection fraction and adjudicated, cause-specific hospitalizations after myocardial infarction complicated by heart failure or left ventricular dysfunction.
    Am Heart J. 2019;215:83-90.
    PubMed     Abstract available


  88. CANNON CP, Khan I, Klimchak AC, Sanchez RJ, et al
    Simulation of impact on cardiovascular events due to lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease.
    Am Heart J. 2019;216:30-41.
    PubMed     Abstract available


  89. GIBLETT JP, Clarke S, Zhao T, McCormick LM, et al
    The role of Glucagon-Like Peptide 1 Loading on periprocedural myocardial infarction During elective PCI (GOLD-PCI study): A randomized, placebo-controlled trial.
    Am Heart J. 2019;215:41-51.
    PubMed     Abstract available


  90. LENG W, Yang J, Fan X, Sun Y, et al
    Contemporary invasive management and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction in China: Findings from China Acute Myocardial Infarction (CAMI) Registry.
    Am Heart J. 2019;215:1-11.
    PubMed     Abstract available


  91. MANNER DH, Battioui C, Hantel S, Beasley BN, et al
    Restricted mean survival time for the analysis of cardiovascular outcome trials assessing non-inferiority: Case studies from antihyperglycemic drug development.
    Am Heart J. 2019;215:178-186.
    PubMed     Abstract available


  92. STROM JB, Tamez H, Zhao Y, Valsdottir LR, et al
    Validating the use of registries and claims data to support randomized trials: Rationale and design of the Extending Trial-Based Evaluations of Medical Therapies Using Novel Sources of Data (EXTEND) Study.
    Am Heart J. 2019;212:64-71.
    PubMed     Abstract available


    May 2019
  93. CLAEYS MJ, Coussement P, Dubois P, Garcia-Dorado D, et al
    Clinical effects of cyclosporine in acute anterior myocardial infarction complicated by heart failure: A subgroup analysis of the CIRCUS Trial.
    Am Heart J. 2019 May 30. pii: S0002-8703(19)30129.
    PubMed    



  94. Correction to "Sex differences in long-term outcomes of patients across the spectrum of coronary artery disease", [American Heart Journal (December 2018) 51-60].
    Am Heart J. 2019 May 29. pii: S0002-8703(19)30112.
    PubMed    


  95. MESSERLI M, Panadero AL, Giannopoulos AA, Schwyzer M, et al
    Enhanced radiation exposure associated with anterior-posterior x-ray tube position in young women undergoing cardiac computed tomography.
    Am Heart J. 2019;215:91-94.
    PubMed     Abstract available


  96. FANAROFF AC, Vora AN, Chen AY, Mathews R, et al
    Hospital participation in clinical trials for patients with acute myocardial infarction: Results from the National Cardiovascular Data Registry.
    Am Heart J. 2019;214:184-193.
    PubMed     Abstract available


  97. YING T, Gill J, Webster A, Kim SJ, et al
    Canadian-Australasian Randomised trial of screening kidney transplant candidates for coronary artery disease-A trial protocol for the CARSK study.
    Am Heart J. 2019;214:175-183.
    PubMed     Abstract available


  98. PUYMIRAT E, Cayla G, Cottin Y, Elbaz M, et al
    Twenty-year trends in profile, management and outcomes of patients with ST-segment elevation myocardial infarction according to use of reperfusion therapy: Data from the FAST-MI program 1995-2015.
    Am Heart J. 2019;214:97-106.
    PubMed     Abstract available


  99. TOTH G, Brodmann M, Barbato E, Mangiacapra F, et al
    Rational and design of the INtentional COronary revascularization versus conservative therapy in patients undergOing successful peripheRAl arTEry revascularization due to critical limb ischemia trial (INCORPORATE trial).
    Am Heart J. 2019;214:107-112.
    PubMed     Abstract available


  100. SHARMA A, Hagstrom E, Wojdyla DM, Neely ML, et al
    Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial.
    Am Heart J. 2019;215:106-113.
    PubMed     Abstract available


  101. MENTIAS A, Shantha G, Adeola O, Barnes GD, et al
    Role of diabetes and insulin use in the risk of stroke and acute myocardial infarction in patients with atrial fibrillation: A Medicare analysis.
    Am Heart J. 2019;214:158-166.
    PubMed     Abstract available


  102. GAZIANO TA, Pandya A, Sy S, Jardim TV, et al
    Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States.
    Am Heart J. 2019;214:77-87.
    PubMed     Abstract available


  103. GELMAN A, Carlin JB, Nallamothu BK
    Objective Randomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina (ORBITA) and coronary stents: A case study in the analysis and reporting of clinical trials.
    Am Heart J. 2019;214:54-59.
    PubMed    


  104. DOUCET S, Jolicoeur EM, Serruys PW, Ragosta M 3rd, et al
    Outcomes of left main revascularization in patients with acute coronary syndromes and stable ischemic heart disease: Analysis from the EXCEL trial.
    Am Heart J. 2019;214:9-17.
    PubMed     Abstract available


  105. RASMUSSEN LD, Winther S, Westra J, Isaksen C, et al
    Danish study of Non-Invasive testing in Coronary Artery Disease 2 (Dan-NICAD 2): Study design for a controlled study of diagnostic accuracy.
    Am Heart J. 2019;215:114-128.
    PubMed     Abstract available


  106. GUDNADOTTIR GS, James SK, Andersen K, Lagerqvist B, et al
    Outcomes after STEMI in old multimorbid patients with complex health needs and the effect of invasive management.
    Am Heart J. 2019;211:11-21.
    PubMed     Abstract available


    April 2019
  107. ZIMMERMANN FM, De Bruyne B, Pijls NHJ, Desai M, et al
    A protocol update of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3 trial: A comparison of fractional flow reserve-guided percutaneous coronary intervention and coronary artery bypass graft surgery in patients with
    Am Heart J. 2019;214:156-157.
    PubMed    


  108. QINTAR M, Hirai T, Arnold SV, Sheehy J, et al
    De-escalation of antianginal medications after successful chronic total occlusion percutaneous coronary intervention: Frequency and relationship with health status.
    Am Heart J. 2019;214:1-8.
    PubMed     Abstract available


  109. VAN DEN BERG MJ, van der Graaf Y, Deckers JW, de Kanter W, et al
    Smoking cessation and risk of recurrent cardiovascular events and mortality after a first manifestation of arterial disease.
    Am Heart J. 2019;213:112-122.
    PubMed     Abstract available


  110. INOHARA T, Shrader P, Pieper K, Blanco RG, et al
    Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II.
    Am Heart J. 2019;213:81-90.
    PubMed     Abstract available


  111. AKERBLOM A, Wojdyla DM, Wallentin L, James SK, et al
    Ticagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.
    Am Heart J. 2019;213:57-65.
    PubMed     Abstract available


  112. GUTIERREZ JA, Bhatt DL, Banerjee S, Glorioso TJ, et al
    Risk of obstructive coronary artery disease and major adverse cardiac events in patients with noncoronary atherosclerosis: Insights from the Veterans Affairs Clinical Assessment, Reporting, and Tracking (CART) Program.
    Am Heart J. 2019;213:47-56.
    PubMed     Abstract available


  113. SULLIVAN LT 2ND, Mulder H, Chiswell K, Shaw LK, et al
    Racial differences in long-term outcomes among black and white patients with drug-eluting stents.
    Am Heart J. 2019;214:46-53.
    PubMed     Abstract available


  114. DECKER PA, Larson NB, Bell EJ, Pankow JS, et al
    Increased hepatocyte growth factor levels over 2 years are associated with coronary heart disease: the Multi-Ethnic Study of Atherosclerosis (MESA).
    Am Heart J. 2019;213:30-34.
    PubMed     Abstract available


  115. YANDRAPALLI S, Sanaani A, Harikrishnan P, Aronow WS, et al
    Cardiogenic shock during heart failure hospitalizations: Age-, sex-, and race-stratified trends in incidence and outcomes.
    Am Heart J. 2019;213:18-29.
    PubMed     Abstract available


  116. VAN ZANDVOORT LJC, Masdjedi K, Tovar Forero MN, Lenzen MJ, et al
    Fractional flow reserve guided percutaneous coronary intervention optimization directed by high-definition intravascular ultrasound versus standard of care: Rationale and study design of the prospective randomized FFR-REACT trial.
    Am Heart J. 2019;213:66-72.
    PubMed     Abstract available


  117. VROEGINDEWEY MM, van den Berg VJ, Bouwens E, Akkerhuis KM, et al
    Temporal evolution of myeloperoxidase and galectin 3 during 1 year after acute coronary syndrome admission.
    Am Heart J. 2019 Apr 6. pii: S0002-8703(19)30052.
    PubMed     Abstract available


  118. HSU S
    Response to the letter to the editor regarding the results of the retrospective study "Predictors of intra-aortic balloon pump hemodynamic failure in non-acute myocardial infarction cardiogenic shock" published in the American Heart Journal.
    Am Heart J. 2019 Apr 6. pii: S0002-8703(19)30067.
    PubMed    


    March 2019
  119. SACCO A, Morici N, Oliva F
    Letter to the editor regarding the results of the retrospective study "Predictors of intra-aortic balloon pump hemodynamic failure in non-acute myocardial infarction cardiogenic shock" published in the American Heart Journal.
    Am Heart J. 2019 Mar 23. pii: S0002-8703(19)30056.
    PubMed    


  120. JENSEN LO, Maeng M, Raungaard B, Engstrom T, et al
    Comparison of the polymer-free biolimus-coated BioFreedom stent with the thin-strut biodegradable polymer sirolimus-eluting Orsiro stent in an all-comers population treated with percutaneous coronary intervention: Rationale and design of the randomize
    Am Heart J. 2019;213:1-7.
    PubMed     Abstract available


  121. XING Y, Liu J, Hao Y, Liu J, et al
    Prehospital statin use and low-density lipoprotein cholesterol levels at admission in acute coronary syndrome patients with history of myocardial infarction or revascularization: Findings from the Improving Care for Cardiovascular Disease in China (CC
    Am Heart J. 2019;212:120-128.
    PubMed     Abstract available


  122. PUMILL CA, Bush CG, Greiner MA, Hall ME, et al
    Neck circumference and cardiovascular outcomes: Insights from the Jackson Heart Study.
    Am Heart J. 2019;212:72-79.
    PubMed     Abstract available


  123. KIM C, Hong SJ, Shin DH, Kim BK, et al
    Randomized evaluation of ticagrelor monotherapy after 3-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with new-generation sirolimus-eluting stents: TICO trial rationale and design.
    Am Heart J. 2019;212:45-52.
    PubMed     Abstract available


  124. ANGRAAL S, Gupta A, Khera R, Nasir K, et al
    Association of access to exercise opportunities and cardiovascular mortality.
    Am Heart J. 2019;212:152-156.
    PubMed     Abstract available


  125. YUDI MB, Clark DJ, Farouque O, Andrianopoulos N, et al
    Trends and predictors of recurrent acute coronary syndrome hospitalizations and unplanned revascularization after index acute myocardial infarction treated with percutaneous coronary intervention.
    Am Heart J. 2019;212:134-143.
    PubMed     Abstract available


  126. HOFFMANN U, Lu MT, Olalere D, Adami EC, et al
    Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers.
    Am Heart J. 2019;212:1-12.
    PubMed     Abstract available


  127. YANG N, Liu J, Liu J, Hao Y, et al
    Performance on management strategies with Class I Recommendation and A Level of Evidence among hospitalized patients with non-ST-segment elevation acute coronary syndrome in China: Findings from the Improving Care for Cardiovascular Disease in China-A
    Am Heart J. 2019;212:80-90.
    PubMed     Abstract available


  128. LIP GYH, Mauri L, Montalescot G, Ozkor M, et al
    Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial.
    Am Heart J. 2019;212:13-22.
    PubMed     Abstract available


  129. FRIGOLI E, Smits P, Vranckx P, Ozaki Y, et al
    Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study.
    Am Heart J. 2019;209:97-105.
    PubMed     Abstract available


    February 2019
  130. BULLUCK H, Frohlich GM, Nicholas JM, Mohdnazri S, et al
    Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial.
    Am Heart J. 2019;211:60-67.
    PubMed     Abstract available


  131. FINN MT, Redfors B, Karmpaliotis D, Kirtane AJ, et al
    Adverse events in patients with high platelet reactivity following successful chronic total occlusion PCI: The Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study.
    Am Heart J. 2019;211:68-76.
    PubMed     Abstract available


  132. TANG X, Zhang D, He L, Wu N, et al
    Performance of atherosclerotic cardiovascular risk prediction models in a rural Northern Chinese population: Results from the Fangshan Cohort Study.
    Am Heart J. 2019;211:34-44.
    PubMed     Abstract available


    January 2019
  133. BLAKE SR, Shahzad A, Aggarwal SK, Kumar A, et al
    Radial versus femoral vascular access in ST-elevation myocardial infarction: Are the results of femoral operators unfairly represented in observational research?
    Am Heart J. 2019;210:81-87.
    PubMed     Abstract available


  134. HERTZ JT, Madut DB, Tesha RA, William G, et al
    Knowledge of myocardial infarction symptoms and perceptions of self-risk in Tanzania.
    Am Heart J. 2019;210:69-74.
    PubMed     Abstract available


  135. FERRARI R, Ford I, Fox K, Marzilli M, et al
    A randomized, double-blind, placebo-controlled trial to assess the efficAcy and safety of Trimetazidine in patients with angina pectoris having been treated by percutaneous coronary intervention (ATPCI study): Rationale, design, and baseline character
    Am Heart J. 2019;210:98-107.
    PubMed     Abstract available


  136. KOSMIDOU I, Redfors B, Chen S, Crowley A, et al
    C-reactive protein and prognosis after percutaneous coronary intervention and bypass graft surgery for left main coronary artery disease: Analysis from the EXCEL trial.
    Am Heart J. 2019;210:49-57.
    PubMed     Abstract available


  137. ALVI RM, Afshar M, Neilan AM, Tariq N, et al
    Heart failure and adverse heart failure outcomes among persons living with HIV in a US tertiary medical center.
    Am Heart J. 2019;210:39-48.
    PubMed     Abstract available


  138. YEBYO HG, Aschmann HE, Kaufmann M, Puhan MA, et al
    Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants.
    Am Heart J. 2019;210:18-28.
    PubMed     Abstract available


    December 2018
  139. DESCH S, Freund A, Graf T, Fichtlscherer S, et al
    Immediate unselected coronary angiography versus delayed triage in survivors of out-of-hospital cardiac arrest without ST-segment elevation: Design and rationale of the TOMAHAWK trial.
    Am Heart J. 2018;209:20-28.
    PubMed     Abstract available


  140. IBRAHIM NE, McCarthy CP, Shrestha S, Lyass A, et al
    Blood kidney injury molecule-1 predicts short and longer term kidney outcomes in patients undergoing diagnostic coronary and/or peripheral angiography-Results from the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study.
    Am Heart J. 2018;209:36-46.
    PubMed     Abstract available


  141. WANG X, Tian M, Zheng Z, Gao H, et al
    Rationale and design of a multicenter randomized trial to compare the graft patency between no-touch vein harvesting technique and conventional approach in coronary artery bypass graft surgery.
    Am Heart J. 2018;210:75-80.
    PubMed     Abstract available


  142. FORDYCE CB, Chen AY, Wang TY, Lucas J, et al
    Patterns of use of targeted temperature management for acute myocardial infarction patients following out-of-hospital cardiac arrest: Insights from the National Cardiovascular Data Registry.
    Am Heart J. 2018;206:131-133.
    PubMed     Abstract available


    November 2018
  143. GIBSON CM, Kerneis M, Yee MK, Daaboul Y, et al
    The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction.
    Am Heart J. 2018;208:81-90.
    PubMed     Abstract available


  144. DOLL JA, Hellkamp AS, Thomas L, Fonarow GC, et al
    The association of pre- and posthospital medication adherence in myocardial infarction patients.
    Am Heart J. 2018;208:74-80.
    PubMed     Abstract available


  145. HEAD T, Henn L, Andreev VP, Herderick EE, et al
    Accelerated coronary atherosclerosis not explained by traditional risk factors in 13% of young individuals.
    Am Heart J. 2018;208:47-54.
    PubMed     Abstract available


  146. PAGIDIPATI NJ, Coles A, Hemal K, Lee KL, et al
    Sex differences in management and outcomes of patients with stable symptoms suggestive of coronary artery disease: Insights from the PROMISE trial.
    Am Heart J. 2018;208:28-36.
    PubMed     Abstract available


  147. POLCWIARTEK C, Behrndtz P, Andersen AH, Bregendahl M, et al
    Attitudes and considerations of patients with ST-elevation myocardial infarction toward participation in randomized clinical trials.
    Am Heart J. 2018;208:21-27.
    PubMed    


  148. HELD C, White HD, Stewart RAH, Davies R, et al
    Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial.
    Am Heart J. 2018;208:65-73.
    PubMed     Abstract available


  149. TRAN HV, Ash AS, Gore JM, Darling CE, et al
    Twenty-five year trends (1986-2011) in hospital incidence and case-fatality rates of ventricular tachycardia and ventricular fibrillation complicating acute myocardial infarction.
    Am Heart J. 2018;208:1-10.
    PubMed     Abstract available


    October 2018
  150. LAMBRAKIS K, French JK, Scott IA, Briffa T, et al
    The appropriateness of coronary investigation in myocardial injury and type 2 myocardial infarction (ACT-2): A randomized trial design.
    Am Heart J. 2018;208:11-20.
    PubMed     Abstract available


  151. MUNKHAUGEN J, Ruddox V, Halvorsen S, Dammen T, et al
    BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study.
    Am Heart J. 2018;208:37-46.
    PubMed     Abstract available


  152. MACHLINE-CARRION MJ, Soares RM, Damiani LP, Campos VB, et al
    Rationale and design for a cluster randomized quality-improvement trial to increase the uptake of evidence-based therapies for patients at high cardiovascular risk: The BRIDGE-Cardiovascular Prevention trial.
    Am Heart J. 2018;207:40-48.
    PubMed     Abstract available


  153. PAGIDIPATI NJ, Mudrick DW, Chiswell K, Brucker A, et al
    Sex differences in long-term outcomes of patients across the spectrum of coronary artery disease.
    Am Heart J. 2018;206:51-60.
    PubMed     Abstract available


    September 2018
  154. PRADHAN AD, Paynter NP, Everett BM, Glynn RJ, et al
    Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study.
    Am Heart J. 2018;206:80-93.
    PubMed     Abstract available


  155. GUEDENEY P, Baber U, Claessen B, Aquino M, et al
    Temporal trends, determinants, and impact of high-intensity statin prescriptions after percutaneous coronary intervention: Results from a large single-center prospective registry.
    Am Heart J. 2018;207:10-18.
    PubMed     Abstract available


  156. HARRISON RW, Radhakrishnan V, Allen JC Jr, Lam PS, et al
    The East-West late lumen loss study: Comparison of angiographic late lumen loss between Eastern and Western drug-eluting stent study cohorts.
    Am Heart J. 2018;206:61-71.
    PubMed     Abstract available


  157. CANNON CP, McGuire DK, Pratley R, Dagogo-Jack S, et al
    Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV).
    Am Heart J. 2018;206:11-23.
    PubMed     Abstract available


    August 2018
  158. ELGENDY IY, Mansoor H, Li Q, Guo Y, et al
    Long-term mortality and estimated functional capacity among women with symptoms of ischemic heart disease: From the NHLBI-sponsored Women's Ischemia Syndrome Evaluation.
    Am Heart J. 2018 Aug 30. pii: S0002-8703(18)30252.
    PubMed     Abstract available


  159. LEE J, Nakanishi R, Li D, Shaikh K, et al
    Randomized trial of rivaroxaban versus warfarin in the evaluation of progression of coronary atherosclerosis.
    Am Heart J. 2018 Aug 24. pii: S0002-8703(18)30249.
    PubMed     Abstract available


  160. ALFONSO F, Cuesta J, Garcia-Guimaraes M, Gonzalez-Barthol E, et al
    Treatment of patients with restenosis of drug-eluting stents.
    Am Heart J. 2018 Aug 24. pii: S0002-8703(18)30250.
    PubMed    


  161. KANG DY, Wong YTA, Park DW, Park SJ, et al
    The authors reply: Treatment of patients with restenosis of drug-eluting stents.
    Am Heart J. 2018 Aug 23. pii: S0002-8703(18)30251.
    PubMed    


  162. MAURI L, Kirtane AJ, Windecker S, Yeh RW, et al
    Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention.
    Am Heart J. 2018;205:110-117.
    PubMed     Abstract available


  163. EINDHOVEN DC, Wu HW, Kremer SWF, van Erkelens JA, et al
    Mortality differences in acute myocardial infarction patients in the Netherlands: The weekend-effect.
    Am Heart J. 2018;205:70-76.
    PubMed    


  164. CHUNG CJ, Kirtane AJ, Zhang Y, Witzenbichler B, et al
    Impact of high on-aspirin platelet reactivity on outcomes following successful percutaneous coronary intervention with drug-eluting stents.
    Am Heart J. 2018;205:77-86.
    PubMed     Abstract available


  165. LAURSEN PN, Holmvang L, Lonborg J, Kober L, et al
    Comparison between patients included in randomized controlled trials of ischemic heart disease and real-world data. A nationwide study.
    Am Heart J. 2018;204:128-138.
    PubMed     Abstract available


  166. MACK MJ, Abraham WT, Lindenfeld J, Bolling SF, et al
    Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial.
    Am Heart J. 2018;205:1-11.
    PubMed     Abstract available


    July 2018
  167. BURGESS SN, French JK, Nguyen TL, Leung M, et al
    The impact of incomplete revascularization on early and late outcomes in ST-elevation myocardial infarction.
    Am Heart J. 2018;205:31-41.
    PubMed     Abstract available


  168. PAGIDIPATI NJ, Hellkamp AS, Sharma PP, Wang TY, et al
    High-sensitivity C-reactive protein elevation in patients with prior myocardial infarction in the United States.
    Am Heart J. 2018;204:151-155.
    PubMed     Abstract available


  169. MORICI N, Oliva F, Ajello S, Stucchi M, et al
    Management of cardiogenic shock in acute decompensated chronic heart failure: The ALTSHOCK phase II clinical trial.
    Am Heart J. 2018 Jul 20. pii: S0002-8703(18)30217.
    PubMed     Abstract available


  170. STEVENS ER, Farrell D, Jumkhawala SA, Ladapo JA, et al
    Quality of health economic evaluations for the ACC/AHA stable ischemic heart disease practice guideline: A systematic review.
    Am Heart J. 2018;204:17-33.
    PubMed     Abstract available


  171. GIBBONS RJ, Weintraub WS, Brindis RG
    Moving from volume to value for revascularization in stable ischemic heart disease: A review.
    Am Heart J. 2018 Jul 10. pii: S0002-8703(18)30108.
    PubMed     Abstract available


  172. HUGELSHOFER S, Roffi M, Witassek F, Eberli FR, et al
    Impact of total ischemic time on manual thrombus aspiration benefit during primary percutaneous coronary intervention.
    Am Heart J. 2018;204:34-42.
    PubMed     Abstract available


  173. GUALANDRO DM, Puelacher C, LuratiBuse G, Lampart A, et al
    Comparison of high-sensitivity cardiac troponin I and T for the prediction of cardiac complications after non-cardiac surgery.
    Am Heart J. 2018;203:67-73.
    PubMed     Abstract available


  174. GNANENTHIRAN SR, Yiannikas J, Lowe HC, Brieger D, et al
    Aspirin hypersensitivity in patients with coronary artery disease: linking pathophysiology to clinical practice.
    Am Heart J. 2018;203:74-81.
    PubMed     Abstract available


  175. RYMER JA, Tempelhof MW, Clare RM, Pieper KS, et al
    Discharge timing and outcomes after uncomplicated non-ST-segment elevation acute myocardial infarction.
    Am Heart J. 2018;201:103-110.
    PubMed     Abstract available


  176. VENETSANOS D, Lawesson SS, James S, Koul S, et al
    Bivalirudin versus heparin with primary percutaneous coronary intervention.
    Am Heart J. 2018;201:9-16.
    PubMed     Abstract available


  177. INOHARA T, Pieper K, Wojdyla DM, Patel MR, et al
    Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome.
    Am Heart J. 2018;201:25-32.
    PubMed     Abstract available


    June 2018
  178. XU H, Faxen J, Szummer K, Trevisan M, et al
    Dyskalemias and adverse events associated with discharge potassium in acute myocardial infarction.
    Am Heart J. 2018;205:53-62.
    PubMed     Abstract available


  179. CHI G, Kerneis M, Kalayci A, Liu Y, et al
    Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial.
    Am Heart J. 2018;203:17-24.
    PubMed     Abstract available


  180. PAOLI G, Notarangelo MF, Mattioli M, La Sala R, et al
    ALLiance for sEcondary PREvention after an acute coronary syndrome. The ALLEPRE trial: A multicenter fully nurse-coordinated intensive intervention program.
    Am Heart J. 2018;203:12-16.
    PubMed    


  181. GREEN JB, Hernandez AF, D'Agostino RB, Granger CB, et al
    Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics.
    Am Heart J. 2018;203:30-38.
    PubMed     Abstract available


  182. ATZEMA CL, Dorian P, Fang J, Tu JV, et al
    A clinical decision instrument to predict 30-day death and cardiovascular hospitalizations after an emergency department visit for atrial fibrillation: The Atrial Fibrillation in the Emergency Room, Part 2 (AFTER2) study.
    Am Heart J. 2018;203:85-92.
    PubMed     Abstract available


  183. HJORT M, Lindahl B, Baron T, Jernberg T, et al
    Prognosis in relation to high-sensitivity cardiac troponin T levels in patients with myocardial infarction and non-obstructive coronary arteries.
    Am Heart J. 2018;200:60-66.
    PubMed     Abstract available


  184. ISRAR MZ, Heaney LM, Ng LL, Suzuki T, et al
    B-type natriuretic peptide molecular forms for risk stratification and prediction of outcome after acute myocardial infarction.
    Am Heart J. 2018;200:37-43.
    PubMed     Abstract available


  185. CAPLICE NM, DeVoe MC, Choi J, Dahly D, et al
    Randomized placebo controlled trial evaluating the safety and efficacy of single low-dose intracoronary insulin-like growth factor following percutaneous coronary intervention in acute myocardial infarction (RESUS-AMI).
    Am Heart J. 2018;200:110-117.
    PubMed     Abstract available


  186. CARSON JL, Stanworth SJ, Alexander JH, Roubinian N, et al
    Clinical trials evaluating red blood cell transfusion thresholds: An updated systematic review and with additional focus on patients with cardiovascular disease.
    Am Heart J. 2018;200:96-101.
    PubMed     Abstract available


  187. ELFWEN L, Lagedal R, James S, Jonsson M, et al
    Coronary angiography in out-of-hospital cardiac arrest without ST elevation on ECG-Short- and long-term survival.
    Am Heart J. 2018;200:90-95.
    PubMed     Abstract available


  188. WIVIOTT SD, Raz I, Bonaca MP, Mosenzon O, et al
    The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial.
    Am Heart J. 2018;200:83-89.
    PubMed     Abstract available


  189. LATTUCA B, Barber-Chamoux N, Alos B, Sfaxi A, et al
    Impact of video on the understanding and satisfaction of patients receiving informed consent before elective inpatient coronary angiography: A randomized trial.
    Am Heart J. 2018;200:67-74.
    PubMed     Abstract available


  190. PASTORI D, Pignatelli P, Cribari F, Carnevale R, et al
    Time to therapeutic range (TtTR), anticoagulation control, and cardiovascular events in vitamin K antagonists-naive patients with atrial fibrillation.
    Am Heart J. 2018;200:32-36.
    PubMed     Abstract available


  191. LOPES RD, Vora AN, Liaw D, Granger CB, et al
    An open-Label, 2 x 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention:
    Am Heart J. 2018;200:17-23.
    PubMed     Abstract available


    May 2018
  192. ITSIOPOULOS C, Kucianski T, Mayr HL, van Gaal WJ, et al
    The AUStralian MEDiterranean Diet Heart Trial (AUSMED Heart Trial): A randomized clinical trial in secondary prevention of coronary heart disease in a multiethnic Australian population: Study protocol.
    Am Heart J. 2018;203:4-11.
    PubMed     Abstract available


  193. VARDENY O, Udell JA, Joseph J, Farkouh ME, et al
    High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial.
    Am Heart J. 2018;202:97-103.
    PubMed     Abstract available


  194. HOLMEN J, Herlitz J, Axelsson C
    Immediate coronary intervention in prehospital cardiac arrest-Aiming to save lives.
    Am Heart J. 2018 May 22. pii: S0002-8703(18)30158.
    PubMed    


  195. LI S, Blumenthal JA, Shi C, Millican D, et al
    I-CARE randomized clinical trial integrating depression and acute coronary syndrome care in low-resource hospitals in China: Design and rationale.
    Am Heart J. 2018;202:109-115.
    PubMed     Abstract available


  196. JAKOBSEN L, Christiansen EH, Maeng M, Kristensen SD, et al
    Randomized clinical comparison of the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent with the sirolimus-eluting Orsiro stent in patients treated with percutaneous coronary intervention: Rationale and study design of the Scandinavian
    Am Heart J. 2018;202:49-53.
    PubMed     Abstract available


  197. HSU S, Kambhampati S, Sciortino CM, Russell SD, et al
    Predictors of intra-aortic balloon pump hemodynamic failure in non-acute myocardial infarction cardiogenic shock.
    Am Heart J. 2018;199:181-191.
    PubMed     Abstract available


  198. WANG A, Wu A, Wojdyla D, Lopes RD, et al
    Dual antiplatelet therapy for perioperative myocardial infarction following CABG surgery.
    Am Heart J. 2018;199:150-155.
    PubMed     Abstract available


  199. GIANOS E, Schoenthaler A, Guo Y, Zhong J, et al
    Investigation of Motivational Interviewing and Prevention Consults to Achieve Cardiovascular Targets (IMPACT) trial.
    Am Heart J. 2018;199:37-43.
    PubMed     Abstract available


  200. BRINKLEY DM JR, Ho KKL, Drazner MH, Kociol RD, et al
    The prognostic value of the relationship between right atrial and pulmonary capillary wedge pressure in diverse cardiovascular conditions.
    Am Heart J. 2018;199:31-36.
    PubMed     Abstract available


  201. MARWICK TH, Whitmore K, Nicholls SJ, Stanton T, et al
    Rationale and design of a trial to personalize risk assessment in familial coronary artery disease.
    Am Heart J. 2018;199:22-30.
    PubMed     Abstract available


  202. THEODORAKIS MJ, Coleman RL, Feng H, Chan J, et al
    Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants.
    Am Heart J. 2018;199:170-175.
    PubMed    


  203. LACHMAN S, Terbraak MS, Limpens J, Jorstad H, et al
    The prognostic value of heart rate recovery in patients with coronary artery disease: A systematic review and meta-analysis.
    Am Heart J. 2018;199:163-169.
    PubMed     Abstract available


  204. GHARACHOLOU SM, Ijioma NN, Lennon RJ, Rihal CS, et al
    Characteristics and long term outcomes of patients with acute coronary syndromes due to culprit left main coronary artery disease treated with percutaneous coronary intervention.
    Am Heart J. 2018;199:156-162.
    PubMed     Abstract available


  205. YAO X, Gersh BJ, Sangaralingham LR, Shah ND, et al
    Risk of cardiovascular events and incident atrial fibrillation in patients without prior atrial fibrillation: Implications for expanding the indications for anticoagulation.
    Am Heart J. 2018;199:137-143.
    PubMed     Abstract available


  206. BOSWORTH HB, Olsen MK, McCant F, Stechuchak KM, et al
    Telemedicine cardiovascular risk reduction in veterans: The CITIES trial.
    Am Heart J. 2018;199:122-129.
    PubMed     Abstract available


  207. KANG J, Koo BK, Hu X, Lee JM, et al
    Comparison of Fractional FLow Reserve And Intravascular ultrasound-guided Intervention Strategy for Clinical OUtcomes in Patients with InteRmediate Stenosis (FLAVOUR): Rationale and design of a randomized clinical trial.
    Am Heart J. 2018;199:7-12.
    PubMed     Abstract available


  208. VETROVEC GW, Anderson M, Schreiber T, Popma J, et al
    The cVAD registry for percutaneous temporary hemodynamic support: A prospective registry of Impella mechanical circulatory support use in high-risk PCI, cardiogenic shock, and decompensated heart failure.
    Am Heart J. 2018;199:115-121.
    PubMed     Abstract available


    April 2018
  209. PATEL KK, Arnold SV, Chan PS, Tang Y, et al
    Validation of the Seattle angina questionnaire in women with ischemic heart disease.
    Am Heart J. 2018;201:117-123.
    PubMed     Abstract available


  210. SPRUILL TM, Reynolds HR, Dickson VV, Shallcross AJ, et al
    Telephone-based mindfulness training to reduce stress in women with myocardial infarction: Rationale and design of a multicenter randomized controlled trial.
    Am Heart J. 2018;202:61-67.
    PubMed     Abstract available


  211. O'NEILL WW, Grines C, Schreiber T, Moses J, et al
    Analysis of outcomes for 15,259 US patients with acute myocardial infarction cardiogenic shock (AMICS) supported with the Impella device.
    Am Heart J. 2018;202:33-38.
    PubMed     Abstract available


  212. PENNY WF, Henry TD, Watkins MW, Patel AN, et al
    Design of a Phase 3 trial of intracoronary administration of human adenovirus 5 encoding human adenylyl cyclase type 6 (RT-100) gene transfer in patients with heart failure with reduced left ventricular ejection fraction: The FLOURISH Clinical Trial.
    Am Heart J. 2018;201:111-116.
    PubMed     Abstract available


  213. MUHLESTEIN JB, May HT, Galenko O, Knowlton KU, et al
    GlycA and hsCRP are independent and additive predictors of future cardiovascular events among patients undergoing angiography: The intermountain heart collaborative study.
    Am Heart J. 2018;202:27-32.
    PubMed     Abstract available


  214. RAVAL AN, Cook TD, Duckers HJ, Johnston PV, et al
    The CardiAMP Heart Failure trial: A randomized controlled pivotal trial of high-dose autologous bone marrow mononuclear cells using the CardiAMP cell therapy system in patients with post-myocardial infarction heart failure: Trial rationale and study d
    Am Heart J. 2018;201:141-148.
    PubMed     Abstract available


  215. FORD TJ, Corcoran D, Oldroyd KG, McEntegart M, et al
    Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Angina (CorMicA) stratified medicine clinical trial.
    Am Heart J. 2018;201:86-94.
    PubMed     Abstract available


  216. RYMER JA, Kaltenbach LA, Anstrom KJ, Fonarow GC, et al
    Hospital evaluation of health literacy and associated outcomes in patients after acute myocardial infarction.
    Am Heart J. 2018;198:97-107.
    PubMed     Abstract available


  217. CHEW DS, Wilton SB, Kavanagh K, Southern DA, et al
    Left ventricular ejection fraction reassessment post-myocardial infarction: Current clinical practice and determinants of adverse remodeling.
    Am Heart J. 2018;198:91-96.
    PubMed     Abstract available


  218. KINNAIRD T, Cockburn J, Gallagher S, Choudhury A, et al
    Temporal changes in radial access use, associates and outcomes in patients undergoing PCI using rotational atherectomy between 2007 and 2014: results from the British Cardiovascular Intervention Society national database.
    Am Heart J. 2018;198:46-54.
    PubMed     Abstract available


  219. CACOUB P, Nahon P, Layese R, Blaise L, et al
    Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients.
    Am Heart J. 2018;198:4-17.
    PubMed     Abstract available


  220. BISHAWI M, Hattler B, Almassi GH, Spertus JA, et al
    Preoperative factors associated with worsening in health-related quality of life following coronary artery bypass grafting in the Randomized On/Off Bypass (ROOBY) trial.
    Am Heart J. 2018;198:33-38.
    PubMed     Abstract available


  221. AL RIFAI M, Greenland P, Blaha MJ, Michos ED, et al
    Factors of health in the protection against death and cardiovascular disease among adults with subclinical atherosclerosis.
    Am Heart J. 2018;198:180-188.
    PubMed     Abstract available


  222. NAVAR AM, Pencina MJ, Mulder H, Elias P, et al
    Improving patient risk communication: Translating cardiovascular risk into standardized risk percentiles.
    Am Heart J. 2018;198:18-24.
    PubMed     Abstract available


  223. TOMASELLI G, Roach WH, Pina IL, Oster ME, et al
    Government continues to have an important role in promoting cardiovascular health.
    Am Heart J. 2018;198:160-165.
    PubMed    


  224. BOWMAN L, Mafham M, Stevens W, Haynes R, et al
    ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes.
    Am Heart J. 2018;198:135-144.
    PubMed     Abstract available


  225. BATCHELOR W, Dahya V, McGee D, Katopodis J, et al
    Ultrahigh-resolution ultrasound characterization of access site trauma and intimal hyperplasia following use of a 7F sheathless guide versus 6F sheath/guide combination for transradial artery PCI: Results of the PRAGMATIC trial.
    Am Heart J. 2018;198:75-83.
    PubMed     Abstract available


  226. VAN DER HEIJDEN LC, Kok MM, Zocca P, Jessurun GAJ, et al
    Bioresorbable Polymer-Coated Orsiro Versus Durable Polymer-Coated Resolute Onyx Stents (BIONYX): Rationale and design of the randomized TWENTE IV multicenter trial.
    Am Heart J. 2018;198:25-32.
    PubMed     Abstract available


  227. BERGMEIJER TO, Reny JL, Pakyz RE, Gong L, et al
    Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC).
    Am Heart J. 2018;198:152-159.
    PubMed     Abstract available


  228. BERWANGER O, de Barros E Silva PGM, Dall Orto FTC, de Andrade PB, et al
    Rationale and design of the Statins Evaluation in Coronary procedUres and REvascularization: The SECURE-PCI Trial.
    Am Heart J. 2018;198:129-134.
    PubMed     Abstract available


    March 2018
  229. BOHULA EA, Scirica BM, Fanola C, Inzucchi SE, et al
    Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial.
    Am Heart J. 2018;202:39-48.
    PubMed     Abstract available


  230. BERWANGER O, Nicolau JC, Carvalho AC, Jiang L, et al
    Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial.
    Am Heart J. 2018;202:89-96.
    PubMed     Abstract available


  231. LOOP MS, McClure LA, Levitan EB, Al-Hamdan MZ, et al
    Fine particulate matter and incident coronary heart disease in the REGARDS cohort.
    Am Heart J. 2018;197:94-102.
    PubMed     Abstract available


  232. SHAVADIA JS, French W, Hellkamp AS, Thomas L, et al
    Comprehensive electrocardiogram-to-device time for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: A report from the American Heart Association mission: Lifeline program.
    Am Heart J. 2018;197:9-17.
    PubMed     Abstract available


  233. HAYS AG, Iantorno M, Schar M, Lai S, et al
    The influence of febuxostat on coronary artery endothelial dysfunction in patients with coronary artery disease: A phase 4 randomized, placebo-controlled, double-blind, crossover trial.
    Am Heart J. 2018;197:85-93.
    PubMed     Abstract available


  234. SONG YB, Oh SK, Oh JH, Im ES, et al
    Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trial.
    Am Heart J. 2018;197:77-84.
    PubMed     Abstract available


  235. EGGERS KM, Jernberg T, Lindahl B
    High-sensitivity cardiac troponin T, left ventricular function, and outcome in non-ST elevation acute coronary syndrome.
    Am Heart J. 2018;197:70-76.
    PubMed     Abstract available


  236. LAGEDAL R, Elfwen L, James S, Oldgren J, et al
    Design of DISCO-Direct or Subacute Coronary Angiography in Out-of-Hospital Cardiac Arrest study.
    Am Heart J. 2018;197:53-61.
    PubMed     Abstract available


  237. WONG YTA, Kang DY, Lee JB, Rha SW, et al
    Comparison of drug-eluting stents and drug-coated balloon for the treatment of drug-eluting coronary stent restenosis: A randomized RESTORE trial.
    Am Heart J. 2018;197:35-42.
    PubMed     Abstract available


  238. REDFORS B, Genereux P, Witzenbichler B, Maehara A, et al
    Percutaneous coronary intervention of lesions with in-stent restenosis: A report from the ADAPT-DES study.
    Am Heart J. 2018;197:142-149.
    PubMed     Abstract available


  239. KOPIN D, Jones WS, Sherwood MW, Wojdyla DM, et al
    Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial.
    Am Heart J. 2018;197:133-141.
    PubMed     Abstract available


  240. HWANG D, Park KW, Lee JM, Rhee TM, et al
    Efficacy and safety of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease.
    Am Heart J. 2018;197:103-112.
    PubMed     Abstract available


  241. SHERWOOD MW, Lopes RD, Sun JL, Liaw D, et al
    Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial.
    Am Heart J. 2018;197:1-8.
    PubMed     Abstract available


  242. CZARNY MJ, Miller JM, Naiman DQ, Hwang CW, et al
    Nonprimary PCI at hospitals without cardiac surgery on-site: Consistent outcomes for all?
    Am Heart J. 2018;197:18-26.
    PubMed     Abstract available


    February 2018
  243. LENG WX, Yang J, Li W, Wang Y, et al
    Rationale and design of the DEAR-OLD trial: Randomized evaluation of routinely Deferred versus EARly invasive strategy in elderly patients of 75 years or OLDer with non-ST-elevation myocardial infarction.
    Am Heart J. 2018;196:65-73.
    PubMed     Abstract available


  244. BAGAI A, Goodman SG, Cantor WJ, Vicaut E, et al
    Duration of ischemia and treatment effects of pre- versus in-hospital ticagrelor in patients with ST-segment elevation myocardial infarction: Insights from the ATLANTIC study.
    Am Heart J. 2018;196:56-64.
    PubMed     Abstract available


  245. GUIMARAES PO, Leonardi S, Huang Z, Wallentin L, et al
    Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
    Am Heart J. 2018;196:28-35.
    PubMed     Abstract available


  246. KILIC S, Fabris E, Van't Hof AWJ, Hamm CW, et al
    Thrombus aspiration and prehospital ticagrelor administration in ST-elevation myocardial infarction: Findings from the ATLANTIC trial.
    Am Heart J. 2018;196:1-8.
    PubMed     Abstract available


  247. DUPRE ME, Xu H, Granger BB, Lynch SM, et al
    Access to routine care and risks for 30-day readmission in patients with cardiovascular disease.
    Am Heart J. 2018;196:9-17.
    PubMed     Abstract available


  248. MCCARTHY CP, McEvoy JW, Januzzi JL Jr.
    Biomarkers in stable coronary artery disease.
    Am Heart J. 2018;196:82-96.
    PubMed     Abstract available


  249. ANYANWAGU U, Mamza J, Donnelly R, Idris I, et al
    Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: A large retrospective UK cohort study.
    Am Heart J. 2018;196:18-27.
    PubMed     Abstract available


  250. KHAZANIE P, Al-Khatib SM, Wang TY, Crowley MJ, et al
    Training cardiovascular outcomes researchers: A survey of mentees and mentors to identify critical training gaps and needs.
    Am Heart J. 2018;196:170-177.
    PubMed     Abstract available


  251. CROWLEY MJ, Al-Khatib SM, Wang TY, Khazanie P, et al
    How well does early-career investigators' cardiovascular outcomes research training align with funded outcomes research?
    Am Heart J. 2018;196:163-169.
    PubMed     Abstract available


  252. VRANCKX P, Lewalter T, Valgimigli M, Tijssen JG, et al
    Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial
    Am Heart J. 2018;196:105-112.
    PubMed     Abstract available


  253. LAURIDSEN KG, Schmidt AS, Adelborg K, Bach L, et al
    Effects of hyperoxia on myocardial injury following cardioversion-A randomized clinical trial.
    Am Heart J. 2018;196:97-104.
    PubMed     Abstract available


  254. SCIAHBASI A, Frigoli E, Sarandrea A, Calabro P, et al
    Determinants of radiation dose during right transradial access: Insights from the RAD-MATRIX study.
    Am Heart J. 2018;196:113-118.
    PubMed     Abstract available


    January 2018
  255. AFANA M, Gurm HS, Seth M, Frazier KM, et al
    Primary percutaneous coronary intervention at centers with and without on-site surgical support: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
    Am Heart J. 2018;195:99-107.
    PubMed     Abstract available


  256. TARANTINI G, Ueshima D, D'Amico G, Masiero G, et al
    Efficacy and safety of potent platelet P2Y12 receptor inhibitors in elderly versus nonelderly patients with acute coronary syndrome: A systematic review and meta-analysis.
    Am Heart J. 2018;195:78-85.
    PubMed     Abstract available


  257. ISSA OM, Roberts R, Mark DB, Boineau R, et al
    Effect of high-dose oral multivitamins and minerals in participants not treated with statins in the randomized Trial to Assess Chelation Therapy (TACT).
    Am Heart J. 2018;195:70-77.
    PubMed     Abstract available


  258. BOSSARD M, Binbraik Y, Beygui F, Pitt B, et al
    Mineralocorticoid receptor antagonists in patients with acute myocardial infarction - A systematic review and meta-analysis of randomized trials.
    Am Heart J. 2018;195:60-69.
    PubMed     Abstract available


  259. LIU E, Hsueh L, Kim H, Vidovich MI, et al
    Global geographical variation in patient characteristics in percutaneous coronary intervention clinical trials: A systematic review and meta-analysis.
    Am Heart J. 2018;195:39-49.
    PubMed     Abstract available


  260. HESS PL, Kennedy K, Cowherd M, Virani SS, et al
    Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project.
    Am Heart J. 2018;195:151-152.
    PubMed    


  261. VEMULAPALLI S, Holmes DR Jr, Dai D, Matsouaka R, et al
    Valve hemodynamic deterioration and cardiovascular outcomes in TAVR: A report from the STS/ACC TVT Registry.
    Am Heart J. 2018;195:1-13.
    PubMed     Abstract available


    December 2017
  262. ILIESCU CA, Cilingiroglu M, Giza DE, Rosales O, et al
    "Bringing on the light" in a complex clinical scenario: Optical coherence tomography-guided discontinuation of antiplatelet therapy in cancer patients with coronary artery disease (PROTECT-OCT registry).
    Am Heart J. 2017;194:83-91.
    PubMed     Abstract available


  263. QADERDAN K, Vos GA, McAndrew T, Steg PG, et al
    Outcomes in elderly and young patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin versus heparin: Pooled analysis from the EUROMAX and HORIZONS-AMI trials.
    Am Heart J. 2017;194:73-82.
    PubMed     Abstract available


  264. INOHARA T, Numasawa Y, Higashi T, Ueda I, et al
    Predictors of high cost after percutaneous coronary intervention: A review from Japanese multicenter registry overviewing the influence of procedural complications.
    Am Heart J. 2017;194:61-72.
    PubMed     Abstract available


  265. DESAI NR, Kennedy KF, Cohen DJ, Connolly T, et al
    Contemporary risk model for inhospital major bleeding for patients with acute myocardial infarction: The acute coronary treatment and intervention outcomes network (ACTION) registry(R)-Get With The Guidelines (GWTG)(R).
    Am Heart J. 2017;194:16-24.
    PubMed     Abstract available


  266. HIRJI SA, Stevens SR, Shaw LK, Campbell EC, et al
    Predicting risk of cardiac events among ST-segment elevation myocardial infarction patients with conservatively managed non-infarct-related artery coronary artery disease: An analysis of the Duke Databank for Cardiovascular Disease.
    Am Heart J. 2017;194:116-124.
    PubMed     Abstract available


  267. GO AS, Fan D, Sung SH, Inveiss AI, et al
    Contemporary rates and correlates of statin use and adherence in nondiabetic adults with cardiovascular risk factors: The KP CHAMP study.
    Am Heart J. 2017;194:25-38.
    PubMed     Abstract available


    November 2017
  268. MUSTO C, De Felice F, Rigattieri S, Chin D, et al
    Instantaneous wave-free ratio and fractional flow reserve for the assessment of nonculprit lesions during the index procedure in patients with ST-segment elevation myocardial infarction: The WAVE study.
    Am Heart J. 2017;193:63-69.
    PubMed     Abstract available


  269. RUSSO JJ, Goodman SG, Cantor WJ, Ko DT, et al
    Does renal function affect the efficacy or safety of a pharmacoinvasive strategy in patients with ST-elevation myocardial infarction? A meta-analysis.
    Am Heart J. 2017;193:46-54.
    PubMed     Abstract available


  270. AKINTOYE E, Briasoulis A, Afonso L
    Biochemical risk markers and 10-year incidence of atherosclerotic cardiovascular disease: independent predictors, improvement in pooled cohort equation, and risk reclassification.
    Am Heart J. 2017;193:95-103.
    PubMed     Abstract available


  271. LEE PH, Lee JY, Lee CW, Han S, et al
    Long-term outcomes of bypass grafting versus drug-eluting stenting for left main coronary artery disease: Results from the IRIS-MAIN registry.
    Am Heart J. 2017;193:76-83.
    PubMed     Abstract available


  272. DOROS G, Massaro JM, Kandzari DE, Waksman R, et al
    Rationale of a novel study design for the BIOFLOW V study, a prospective, randomized multicenter study to assess the safety and efficacy of the Orsiro sirolimus-eluting coronary stent system using a Bayesian approach.
    Am Heart J. 2017;193:35-45.
    PubMed     Abstract available


  273. CHIANG MH, Wu HH, Shih CJ, Chen YT, et al
    Association between influenza vaccination and reduced risks of major adverse cardiovascular events in elderly patients.
    Am Heart J. 2017;193:1-7.
    PubMed     Abstract available


  274. SHADDY R, Canter C, Halnon N, Kochilas L, et al
    Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study).
    Am Heart J. 2017;193:23-34.
    PubMed     Abstract available


    October 2017
  275. WAKSMAN R, Torguson R, Spad MA, Garcia-Garcia H, et al
    The Lipid-Rich Plaque Study of vulnerable plaques and vulnerable patients: Study design and rationale.
    Am Heart J. 2017;192:98-104.
    PubMed     Abstract available


  276. JESSEE R, Peart E, Beineke P, Rosenberg S, et al
    Rheumatoid arthritis complicates noninvasive whole blood gene expression testing for coronary artery disease.
    Am Heart J. 2017;192:13-18.
    PubMed     Abstract available


  277. DEHGHANI P, Lavoie A, Lavi S, Crawford JJ, et al
    Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI.
    Am Heart J. 2017;192:105-112.
    PubMed     Abstract available


  278. ALBERT MA, Durazo EM, Slopen N, Zaslavsky AM, et al
    Cumulative psychological stress and cardiovascular disease risk in middle aged and older women: Rationale, design, and baseline characteristics.
    Am Heart J. 2017;192:1-12.
    PubMed     Abstract available


    September 2017
  279. WALLERT J, Held C, Madison G, Olsson EM, et al
    Temporal changes in myocardial infarction incidence rates are associated with periods of perceived psychosocial stress: A SWEDEHEART national registry study.
    Am Heart J. 2017;191:12-20.
    PubMed     Abstract available


  280. GUDNADOTTIR GS, Andersen K, Thrainsdottir IS, James SK, et al
    Gender differences in coronary angiography, subsequent interventions, and outcomes among patients with acute coronary syndromes.
    Am Heart J. 2017;191:65-74.
    PubMed     Abstract available


  281. FARB A, Zuckerman BD
    Clinical event adjudication in cardiovascular device trials: An Food and Drug Administration perspective.
    Am Heart J. 2017;191:62-64.
    PubMed    


  282. REN HY, Khera A, de Lemos JA, Ayers CR, et al
    Soluble endothelial cell-selective adhesion molecule and incident cardiovascular events in a multiethnic population.
    Am Heart J. 2017;191:55-61.
    PubMed     Abstract available


  283. KIM Y, Soffler M, Paradise S, Jelani QU, et al
    Depression is associated with recurrent chest pain with or without coronary artery disease: A prospective cohort study in the emergency department.
    Am Heart J. 2017;191:47-54.
    PubMed     Abstract available


  284. WEI J, Mehta PK, Grey E, Garberich RF, et al
    Sex-based differences in quality of care and outcomes in a health system using a standardized STEMI protocol.
    Am Heart J. 2017;191:30-36.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ischemic Heart Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: